Etiology and Prognostic Criteria for Liver Failure in Southeast China: A Multicenter Retrospective Cohort Study Between 2018 and 2020

被引:0
作者
Lyu, Chunyan [1 ,2 ]
Han, Jun [3 ]
Kang, Naling [4 ]
Zeng, Dawu [4 ]
Davgadorj, Chantsalmaa [1 ]
Ge, Lina [1 ]
Zhou, Meifang [3 ]
Mao, Richeng [5 ]
Yan, Yan [1 ,2 ]
机构
[1] Fifth Peoples Hosp Wuxi, Clin Med Res Ctr, Wuxi, Peoples R China
[2] Nantong Univ, Wuxi Clin Coll, Clin Med Resarch Ctr, Wuxi, Peoples R China
[3] Fifth Peoples Hosp Wuxi, Dept Infect Dis, Wuxi, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 1, Dept Infect Dis, Fuzhou, Fujian, Peoples R China
[5] Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China
关键词
acute-on-chronic liver failure; antithrombin III; hepatitis B virus (HBV); liver failure; prognostic; INFLAMMATION; CIRRHOSIS; DISEASE;
D O I
10.1155/grp/5512889
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The prognosis of patients with liver failure (LF) depends significantly on the etiology and clinical indicators. This analysis of these basic indicators can help provide a basis for the study of predictive outcome indicators. Methods: We collected the data from multiple centers in Southeast China, including subclasses of acute liver failure (ALF), subacute liver failure (SLF), acute-on-chronic liver failure (ACLF), subacute-on-chronic liver failure (SALF), and chronic liver failure (CLF). Multivariate logistic regression analysis was used to screen for clinical indicators of nonsurvivors. We analyzed receiver operating characteristic (ROC) curves and cutoff values to assess the prognostic criteria. Results: Hepatitis B virus (HBV) infection is the leading etiology of patients with LF (64.52% (411/637)). SALF (41.36%) and CLF (32.30%) are the main subclasses of the hepatitis B virus-related liver failure (HBV-LF) group and the non-HBV-related LF group in Southeast China, respectively. Between 2018 and 2020, the incidence of HBV-LF decreased significantly, ranging from 72.36% to 59.74%, and the spontaneous survival rates of patients with HBV-LF were substantially lower than those of non-HBV-LF patients (36.43%similar to 44.93% vs. 58.97%similar to 63.64%). Infection and cirrhosis were the leading causes of death in both groups. The age and total bilirubin value of the nonsurvivors with HBV-LF were significantly higher, and the number of days of hospitalization was significantly shorter than that of the survivors. The ages of the nonsurvivors in the non-HBV-LF group were significantly higher than those of the survivors. The prothrombin time-international normalized ratio (PT-INR) is 2.05, 1.92, or 2.11, and antithrombin III (AT III) is 24.50%, which are proposed as prognostic criteria for the HBV-SALF (hepatitis B virus-related subacute-on-chronic liver failure), non-HBV-SLF (non-hepatitis B virus-related subacute liver failure), non-HBV-ACLF (non-hepatitis B virus-related acute-on-chronic liver failure), and HBV-ALF (hepatitis B virus-related acute liver failure) subclasses, respectively. Conclusions: The incidence of HBV-LF is decreasing annually. AT III, as an independent prognostic criterion, has excellent discriminative ability for the outcomes of the HBV-ALF subclass.
引用
收藏
页数:13
相关论文
共 34 条
  • [1] Acute Liver Failure
    Bernal, William
    Wendon, Julia
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (26) : 2525 - 2534
  • [2] The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis
    Cao, Zhujun
    Liu, Yuhan
    Cai, Minghao
    Xu, Yumin
    Xiang, Xiaogang
    Zhao, Gangde
    Cai, Wei
    Wang, Hui
    Wang, Weijing
    Xie, Qing
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (12) : 2026 - 2035
  • [3] Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure
    Casulleras, Mireia
    Zhang, Ingrid W.
    Lopez-Vicario, Cristina
    Claria, Joan
    [J]. CELLS, 2020, 9 (12)
  • [4] Systemic Inflammation in Decompensated Cirrhosis: Characterization and Role in Acute-on-Chronic Liver Failure
    Claria, Joan
    Stauber, Rudolf E.
    Coenraad, Minneke J.
    Moreau, Richard
    Jalan, Rajiv
    Pavesi, Marco
    Amoros, Alex
    Titos, Esther
    Alcaraz-Quiles, Jose
    Oettl, Karl
    Morales-Ruiz, Manuel
    Angeli, Paolo
    Domenicali, Marco
    Alessandria, Carlo
    Gerbes, Alexander
    Wendon, Julia
    Nevens, Frederik
    Trebicka, Jonel
    Laleman, Wim
    Saliba, Faouzi
    Welzel, Tania M.
    Albillos, Agustin
    Gustot, Thierry
    Benten, Daniel
    Durand, Francois
    Gines, Pere
    Bernardi, Mauro
    Arroyo, Vicente
    [J]. HEPATOLOGY, 2016, 64 (04) : 1249 - 1264
  • [5] Acute-on-chronic liver failure: Where do we stand?
    Durand, Francois
    Roux, Olivier
    Weiss, Emmanuel
    Francoz, Claire
    [J]. LIVER INTERNATIONAL, 2021, 41 : 128 - 136
  • [6] Model for end-stage liver disease (MELD) for liver allocation: A 5-year score card
    Freeman, Richard B., Jr.
    [J]. HEPATOLOGY, 2008, 47 (03) : 1052 - 1057
  • [7] Gruttadauria S., 2017, PLoS One, V12
  • [8] Heinz S., 2015, Protocols in In Vitro Hepatocyte Research. Methods in Molecular Biology, V1250, DOI [10.1007/978-1-4939-2074-723, DOI 10.1007/978-1-4939-2074-723]
  • [9] Performance of the Liver Maximum Function Capacity Test, Fibrinogen, and Transient Elastography in Patients with Acute Liver Injury
    Kreimeyer, Henriette
    Buechter, Matthias
    Best, Jan
    Gieseler, Robert K.
    Katsounas, Antonios
    Sowa, Jan-Peter
    Gerken, Guido
    Canbay, Ali
    Manka, Paul
    Bechmann, Lars P.
    [J]. DIGESTIVE DISEASES, 2023, 41 (02) : 259 - 267
  • [10] Kumar D., 2016, J GASTROEN HEPATOL, V31, P856, DOI DOI 10.1111/jgh.13213